These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 30527909

  • 1. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
    Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B.
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
    [Abstract] [Full Text] [Related]

  • 2. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B, Ueda P, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Wintzell V, Melbye M, Svanström H.
    BMJ; 2019 Aug 29; 366():l4772. PubMed ID: 31467044
    [Abstract] [Full Text] [Related]

  • 3. Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.
    Pasternak B, Wintzell V, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Melbye M, Svanström H, Ueda P.
    Diabetes Care; 2020 Jun 29; 43(6):1326-1335. PubMed ID: 32295809
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
    Thomsen RW, Knudsen JS, Kahlert J, Baggesen LM, Lajer M, Holmgaard PH, Vedin O, Ustyugova A, Sørensen HT.
    J Am Heart Assoc; 2021 Jun 29; 10(11):e019356. PubMed ID: 34032121
    [Abstract] [Full Text] [Related]

  • 5. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
    Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA.
    JAMA Cardiol; 2019 Dec 01; 4(12):1214-1220. PubMed ID: 31721979
    [Abstract] [Full Text] [Related]

  • 6. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM.
    Diabetes Obes Metab; 2016 Sep 01; 18(9):916-24. PubMed ID: 27177784
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
    Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group.
    Lancet Diabetes Endocrinol; 2020 Jul 01; 8(7):606-615. PubMed ID: 32559476
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM, Chen HT, Kuo SC, Chen TJ, Shih CJ, Chen YT.
    Heart; 2017 Mar 01; 103(6):414-420. PubMed ID: 27647170
    [Abstract] [Full Text] [Related]

  • 11. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
    Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.
    Circulation; 2018 Dec 18; 138(25):2884-2894. PubMed ID: 30566004
    [Abstract] [Full Text] [Related]

  • 12. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E, Everett BM, Goldfine AB, Glynn RJ, Liu J, Gopalakrishnan C, Kim SC.
    Diabetes Obes Metab; 2016 Aug 18; 18(8):755-65. PubMed ID: 27003762
    [Abstract] [Full Text] [Related]

  • 13. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
    Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P.
    BMJ; 2020 Apr 29; 369():m1186. PubMed ID: 32349963
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ, Chen HT, Kuo SC, Ou SM, Chen YT.
    J Am Med Dir Assoc; 2016 Jan 29; 17(1):59-64. PubMed ID: 26612484
    [Abstract] [Full Text] [Related]

  • 15. Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.
    Crowley MJ, Gokhale M, Pate V, Stürmer T, Buse JB.
    Diabetes Obes Metab; 2019 Apr 29; 21(4):854-865. PubMed ID: 30456843
    [Abstract] [Full Text] [Related]

  • 16. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL, Hsiao FY, Chiang CK, Shen LJ, Huang CF.
    PLoS One; 2019 Apr 29; 14(5):e0215248. PubMed ID: 31112536
    [Abstract] [Full Text] [Related]

  • 17. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
    Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI.
    Diabetes Obes Metab; 2018 Feb 29; 20(2):344-351. PubMed ID: 28771923
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2237606. PubMed ID: 36264574
    [Abstract] [Full Text] [Related]

  • 19. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH, Yin H, Azoulay L.
    Can J Diabetes; 2015 Oct 03; 39(5):383-9. PubMed ID: 25840943
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.